Accepted for/Published in: JMIR Research Protocols
Date Submitted: Apr 22, 2022
Date Accepted: Jun 30, 2022
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Randomized Trial Outcomes for Massage: Care Ally-Assisted vs. Therapist Treated (TOMCATT) Study Methods
ABSTRACT
Background:
Chronic neck pain is prevalent and reduces functional status, quality of life, and is associated with deleterious psychological outcomes in affected individuals. Despite desirability for massage and its demonstrated effectiveness for chronic neck pain, multiple accessibility barriers exist. Caregiver applied massage approaches have demonstrated feasibility in various populations but has not been examined in Veterans with chronic neck pain or compared in parallel to therapist-delivered massage.
Objective:
This manuscript describes the original study design, lessons learned, and resultant design modification for the Trial Outcomes for Massage: Care Ally-Assisted vs. Therapist Treated (TOMCATT) study.
Methods:
TOMCATT began as a 3-arm, randomized controlled trial of two massage delivery approaches for Veterans with chronic neck pain with measures collected at baseline, 1-, 3-(post-intervention), and 6months (follow-up). Arm I: Care ally-assisted massage consisted of: i) in-person, 3.5-hour training workshop, ii) instructional DVD, iii) printed treatment manual, and iv) three, 30-minute at-home care ally-assisted massage sessions weekly for 3 months. Arm II: Therapist treated massage consisted of two, 60-minute tailored to individual pain experience treatments per week for 3 months. Treatments followed a standardized Swedish massage approach protocol. Arm III: Wait-list control.
Results:
Retention and engagement challenges in the first 30 months were significant in the care ally-assisted massage study arm (63% attrition between randomization and treatment initiation) and prompted modification to a 2-arm trial; removing Arm I.
Conclusions:
The modified TOMCATT study successfully launched and exceeded recruitment goals 2.5 months prior to the necessary COVID-19 pause and is expected to be completed by early 2023. Clinical Trial: ClinicalTrials.gov NCT03100539)
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.